476 related articles for article (PubMed ID: 10389938)
21. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
22. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Luqmani YA; Temmim L; Parkar AH; Mathew M
Oncol Rep; 2002; 9(3):645-51. PubMed ID: 11956644
[TBL] [Abstract][Full Text] [Related]
24. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
[TBL] [Abstract][Full Text] [Related]
25. Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium.
Saegusa M; Okayasu I
Jpn J Cancer Res; 2000 May; 91(5):510-8. PubMed ID: 10835496
[TBL] [Abstract][Full Text] [Related]
26. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
27. pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters.
Speiser P; Mayerhofer K; Kucera E; Roch G; Mittelböck M; Gitsch G; Zeillinger R
Anticancer Res; 1997; 17(1B):679-83. PubMed ID: 9066601
[TBL] [Abstract][Full Text] [Related]
28. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
30. [Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors].
Díez Gibert O; Machuca I; Sebastián MA; Rosel P; Navarro MA
Med Clin (Barc); 1996 Jun; 107(3):90-2. PubMed ID: 8754494
[TBL] [Abstract][Full Text] [Related]
31. Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas.
Markićević M; Petrović A; Kanjer K; Nesković-Konstantinović Z; Nikolić-Vukosavujević D
Adv Exp Med Biol; 2008; 617():341-8. PubMed ID: 18497057
[TBL] [Abstract][Full Text] [Related]
32. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
Sereff SB; Daniels MW; Wittliff JL
J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
[TBL] [Abstract][Full Text] [Related]
33. Regulation of Msx2 gene expression by steroid hormones in human nonmalignant and malignant breast cancer explants cultured in vitro.
Malewski T; Milewicz T; Krzysiek J; Gregoraszczuk EL; Augustowska K
Cancer Invest; 2005; 23(3):222-8. PubMed ID: 15945508
[TBL] [Abstract][Full Text] [Related]
34. Coexpression of alternatively spliced estrogen and progesterone receptor transcripts in human breast cancer.
Balleine RL; Hunt SM; Clarke CL
J Clin Endocrinol Metab; 1999 Apr; 84(4):1370-7. PubMed ID: 10199781
[TBL] [Abstract][Full Text] [Related]
35. Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens.
Knowlden JM; Gee JM; Bryant S; McClelland RA; Manning DL; Mansel R; Ellis IO; Blamey RW; Robertson JF; Nicholson RI
Clin Cancer Res; 1997 Nov; 3(11):2165-72. PubMed ID: 9815611
[TBL] [Abstract][Full Text] [Related]
36. Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Zhang Z; Yamashita H; Toyama T; Omoto Y; Sugiura H; Hara Y; Wu X; Kobayashi S; Iwase H
Breast Cancer Res; 2003; 5(6):R250-6. PubMed ID: 14580261
[TBL] [Abstract][Full Text] [Related]
37. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.
Witzel ID; Milde-Langosch K; Wirtz RM; Roth C; Ihnen M; Mahner S; Zu Eulenburg C; Jänicke F; Müller V
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1709-18. PubMed ID: 20204407
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins.
Dotzlaw H; Leygue E; Watson PH; Murphy LC
Cancer Res; 1999 Feb; 59(3):529-32. PubMed ID: 9973194
[TBL] [Abstract][Full Text] [Related]
39. [Expression and clinical significance of LRP16 gene in human breast cancer].
Liao DX; Han WD; Zhao YL; Pu YD; Mu YM; Luo CH; Li XH
Ai Zheng; 2006 Jul; 25(7):866-70. PubMed ID: 16831279
[TBL] [Abstract][Full Text] [Related]
40. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
